Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Briacell Therapeutics Corp (BCTX)

Briacell Therapeutics Corp (BCTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,034
  • Shares Outstanding, K 15,279
  • Annual Sales, $ 0 K
  • Annual Income, $ -430 K
  • 60-Month Beta 1.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.63
Trade BCTX with:

Options Overview Details

View History
  • Implied Volatility 108.11% ( -0.42%)
  • Historical Volatility 112.33%
  • IV Percentile 8%
  • IV Rank 12.51%
  • IV High 203.45% on 10/13/21
  • IV Low 94.48% on 03/24/22
  • Put/Call Vol Ratio 0.27
  • Today's Volume 164
  • Volume Avg (30-Day) 902
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 31,336
  • Open Int (30-Day) 44,812

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/22
See More
  • Average Estimate -0.19
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.21
  • Prior Year -0.93
  • Growth Rate Est. (year over year) +79.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.06 +17.73%
on 05/12/22
7.75 -38.32%
on 04/25/22
-2.67 (-35.84%)
since 04/22/22
3-Month
4.06 +17.73%
on 05/12/22
12.09 -60.46%
on 04/08/22
-2.44 (-33.80%)
since 02/23/22
52-Week
3.00 +59.33%
on 05/24/21
12.47 -61.67%
on 12/01/21
+1.70 (+55.19%)
since 05/21/21

Most Recent Stories

More News
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 2.17 (+3.09%)
BCTX : 4.78 (-4.40%)
BCT.TO : 6.46 (+1.73%)
Why Is BriaCell (BCTX) Stock Moving Today?

BCTX is experiencing heavy trading today

PYPL : 81.18 (+0.79%)
BCTX : 4.78 (-4.40%)
ATRS : 5.59 (unch)
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast...

BCTXW : 2.17 (+3.09%)
BCTX : 4.78 (-4.40%)
BCT.TO : 6.46 (+1.73%)
BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022

Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy.Bria-OTS™ will...

BCTXW : 2.17 (+3.09%)
BCTX : 4.78 (-4.40%)
BCT.TO : 6.46 (+1.73%)
BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial

Bria-OTS™ would build on BriaCell’s existing clinical trial data with Bria-IMT™, treating each patient with the optimized pre-manufactured Bria-OTS™...

BCTXW : 2.17 (+3.09%)
BCTX : 4.78 (-4.40%)
BCT.TO : 6.46 (+1.73%)
BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 2.17 (+3.09%)
BCTX : 4.78 (-4.40%)
BCT.TO : 6.46 (+1.73%)
BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 2.17 (+3.09%)
BCTX : 4.78 (-4.40%)
BCT.TO : 6.46 (+1.73%)
BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or...

BCTXW : 2.17 (+3.09%)
BCTX : 4.78 (-4.40%)
BCT.VN : 10.600 (-3.81%)
BCT.TO : 6.46 (+1.73%)
BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on Nasdaq

BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 29, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)...

BCT.VN : 10.600 (-3.81%)
BCTXW : 2.17 (+3.09%)
BCTX : 4.78 (-4.40%)
BCT.TO : 6.46 (+1.73%)
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy

Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including...

ONCY : 1.0900 (+1.87%)
ONC.TO : 1.35 (-4.26%)
HOLX : 78.81 (+1.36%)
IMGN : 3.57 (-0.28%)
NKTR : 3.57 (-7.99%)
BCTX : 4.78 (-4.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 5.33
2nd Resistance Point 5.19
1st Resistance Point 4.99
Last Price 4.78
1st Support Level 4.65
2nd Support Level 4.51
3rd Support Level 4.31

See More

52-Week High 12.47
Fibonacci 61.8% 8.85
Fibonacci 50% 7.74
Fibonacci 38.2% 6.62
Last Price 4.78
52-Week Low 3.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar